25220 Federal Register / Vol. 63, No. 88 /Thursday, May 7, 1998 / Notices

3. Providing technical expertise and/

or financial support for (e.g. facilities,

personnel and expertise) for CRADArelated Government activities.

4. Accomplishing objectives

according to an appropriate timetable to

be outlined in the CRADA

Collaborator’s proposal.

5. The willingness to commit best

effort and demonstrated resources to the

research, development and

commercialization of this technology.

6. The demonstration of expertise in

the commercial development,

production, marketing and sales of

products related to this area of

technology.

8. The willingness to cooperate with

the National Cancer Institute in the

timely publication of research results.

9. The agreement to be bound by the

appropriate DHHS regulating to human

subjects, and all PHS policies relating to

the use and care of laboratory animals.

10. The willingness to accept the legal

provisions and language of the CRADA

with only minor modifications, if any.

These provisions govern the equitable

distribution of patent rights to CRADA

inventions.

Dated: April 26, 1998.

Kathleen Sybert,

Acting Director, Technology Development &

Commercialization Branch, National Cancer

Institute, National Institutes of Health.

[FR Doc. 98–12110 Filed 5–6–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Aging:

Opportunity for a Cooperative

Research and Development Agreement

(CRADA) To Develop a Vaccine for

Pneumonia

AGENCY: National Institutes of Health

(NIH), PHS, DHHSNIA, NIH, PHS,

DHHS.

ACTION: Notice.

SUMMARY: The National Institute on

Aging (NIA) is seeking a Collaborator to

participate in a Cooperative Research

and Development Agreement (CRADA)

to develop a vaccine for pneumonia.

The term of the CRADA will be up to

five (5) years.

ADDRESESS: Inquiries and proposals

regarding this opportunity should be

addressed to Bruce D. Goldstein, J.D.,

Technology Development and

Commercialization Branch, National

Cancer Institute, 6120 Executive Blvd.,

EPS Suite 450, Rockville, Maryland

20852, telephone number 301–496–

0477, FAX number 301–402–2117.

DATES: interested parties are advised to

notify this office in writing of their

intent to file a formal proposal no later

than FIFTEEN (15) days from the date

of this advertisement. Formal proposals

must be submitted to this office no later

than TWENTY (20) days from the date

of this notice.

SUPPLEMENTARY INFORMATION: A CRADA

is the anticipated joint agreement to be

entered into by NIA pursuant to the

Federal Technology Transfer Act of

1986, a amended by the National

Technology Transfer Act (Pub. L. 104–

113 (Mar. 7, 1996)) and by Executive

Order 12591 of April 10, 1987. The NCI

owns U.S. Patent No. 4,455,032,

concerning the use of phosphocholine

hapten conjugates in vaccines, which

presently is not licensed. NIA is now

planning to develop a vaccine for

pneumonia utilizing the invention in

the NCI patent.

Under the present proposal, the

specific goals of the CRADA will be the

development of the following

technology:

• Development of one or more

vaccines utilizing the phosphocholinehapten technology;

• and preclinical evaluation of the

candidate vaccines.

Party Contributions

The role in NIA includes the

following:

(1) Develop, in cooperation with the

Collaborator, candidate pneumonia

vaccines;

(2) Conduct preclinical trials of

candidate vaccines in small mammal

models;

(3) Provide staff, expertise, &

materials for the development and

testing of promising vaccines, and

provide work space and equipment for

testing of the prototype vaccines; and

(4) Jointly evaluate and publish the

data generated with Collaborator.

The role of the successful Collaborator

will include the following:

(1) Provide an adequate supply of at

least one mutually agreeable, GMPgrade carrier system, and provide

expertise and assistance in the

development and use of its vaccine

carrier system(s);

(2) Provide resources, staff, expertise,

and funding, as necessary, in support of

the research goals; and

(3) Develop and market any promising

vaccines.

Selection Criteria

Proposals submitted for consideration

should fully address each of the

following qualifications:

(1) Expertise:

A. Demonstrated expertise in

developing and producing high quality

pharamacuetical compositions;

B. Demonstrated ability to secure

national and/or international marketing

and distribution of pharmaceutical

compositions;

C. Demonstrated intellectual ability to

guide development of product line

which addresses the requirements of

NIA;

(2) Reputation: The successful

Collaborator must be recognized in the

pharmaceutical industry for:

A. Producing quality pharmaceutical

products;

B. Indications of satisfaction by

industry experts with the Collaborator’s

products; and

C. Commitment to the research and

development of new pharmaceuticals.

(3) Physical Resources:

A. An established headquarters with

offices, space, and equipment;

B. Access to the organization during

business hours by telephone, mail, email, the Internet, and other evolving

technologies; and

C. Sufficient financial resources to

support, at a minimum, the current

activities of the CRADA to meet the

needs of NIA.

Dated: April 26, 1998.

Kathleen Sybert,

Acting Director, Technology Development &

Commercialization Branch, National Cancer

Institute, National Institutes of Health.

[FR Doc. 98–12109 Filed 5–6–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of

Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Center

for Scientific Review Special Emphasis

Panel (SEP) meetings:

Purpose/Agenda: To review individual

grant applications.

Name of SEP: Microbiological and

Immunological Sciences.

Date: May 12, 1998.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4182,

Telephone Conference.

Contact Person: Dr. William Branche,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4182, Bethesda,

Maryland 20892, (301) 435–1148.

Name of SEP: Clinical Sciences.

Date: May 13, 1998.
Federal Register / Vol. 63, No. 88 /Thursday, May 7, 1998 / Notices 25221

Time: 9:30 a.m.

Place: Holiday Inn, Chevy Chase, MD.

Contact Person: Dr. Dan McDonald,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4214, Bethesda,

Maryland 20892, (301) 435–1215

Name of SEP: Microbiological and

Immunological Sciences.

Date: May 13, 1998.

Time: 10:00 a.m.

Place: NIH, Rockledge 2, Room 4182,

Telephone Conference.

Contact Person: Dr. William Branche,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4182, Bethesda,

Maryland 20892, (301) 435–1148.

This notice is being published less than 15

days prior to the above meetings due to the

urgent need to meet timing limitations

imposed by the grant review and funding

cycle.

Name of SEP: Behavioral and

Neurosciences.

Date: May 21, 1998.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 5172,

Telephone Conference.

Contact Person: Dr. Leonard Jakubczak,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5172, Bethesda,

Maryland 20892, (301) 435–1247.

Name of SEP: Behavioral and

Neurosciences.

Date: June 16–18, 1998.

Time: 8:30 a.m.

Place: Doubletree Hotel, Rockville, MD.

Contact Person: Dr. Syed Husain, Scientific

Review Administrator, 6701 Rockledge Drive,

Room 5216, Bethesda, Maryland 20892, (301)

435–1224.

Name of SEP: Behavioral and

Neurosciences.

Date: June 23–25, 1998.

Time: 8:30 a.m.

Place: Radisson Barcelo, Washington, DC.

Contact Person: Dr. Gabrielle LeBlanc,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5218, Bethesda,

Maryland 20892, (301) 435–1218.

Name of SEP: Multidisciplinary Sciences.

Date: June 25, 1998.

Time: 12:00 p.m.

Place: Holiday Inn-Georgetown,

Washington, DC.

Contact Person: Dr. Lee Rosen, Scientific

Review Administrator, 6701 Rockledge Drive,

Room 5116, Bethesda, Maryland 20892, (301)

435–1171.

The meetings will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasions of personal privacy.

(Catalog of Federal Domestic Assistance

Program Nos. 93.306, 93.333, 93.337, 93.393–

93.396, 93.837–93.844, 93.846–93.878,

93.892, 93,893, National Institutes of Health,

HHS)

Dated: April 29, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98–12099 Filed 5–6–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of

Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Center

for Scientific Review Special Emphasis

Panel (SEP) meetings:

Purpose/Agenda: To review individual

grant applications.

Name of SEP: Behavioral and

Neurosciences.

Date: May 12, 1998.

Time: 3:00 p.m.

Place: NIH, Rockledge 2, Room 5172,

Telephone Conference.

Contact Person: Dr. Leonard Jakubczak,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5172, Bethesda,

Maryland 20892, (301) 435–1247.

Name of SEP: Behavioral and

Neurosciences.

Date: May 18, 1998.

Time: 11:00 a.m.

Place: NIH, Rockledge 2, Room 5172,

Telephone Conference.

Contact Person: Dr. Leonard Jakubczak,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5172, Bethesda,

Maryland 20892, (301) 435–1247.

This notice is being published less than 15

days prior to the above meetings due to the

urgent need to meet timing limitations

imposed by the grant review and funding

cycle.

Name of SEP: Chemistry and Related

Sciences.

Date: June 23–24, 1998..

Time: 8:00 a.m..

Place: Hyatt Regency Hotel, Bethesda, MD.

Contact Person: Dr. Marjam Behar,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5218, Bethesda,

Maryland 20892, (301) 435–1180.

The meetings will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Nos. 93.306, 93.333, 93.337, 93.393–

93.396, 93.837–93.844, 93.846–93.878,

93.892, 93.893, National Institutes of Health,

HHS)

Dated: May 1, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98–12101 Filed 5–6–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Cancer Institute Special

Emphasis Panel (SEP) meeting:

Name of SEP: MR Guided Therapy.

Date: May 26–28, 1998.

Time: May 26—7:00 p.m. to Recess, May

27—8:00 a.m. to Recess, May 28–8:00 a.m. to

Adjournment.

Place: The Inn at Longwood Medical, 342

Longwood Avenue, Boston, MA 02115.

Contact Person: Ray Bramhall, Ph.D.,

Scientific Review Administrator, National

Cancer Institute, NIH, Executive Plaza North,

Room 643B, 6130 Executive Boulevard, MSC

7405, Bethesda, MD 20892–7405, Telephone:

301/496–3428.

Purpose/Agenda: To review, discuss and

evaluate grant applications.

The meeting will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material and personal information

concerning individuals associated with the

applications, the disclosure of which would

constitute a clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control)

Dated: April 30, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98–12107 Filed 5–6–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Center for Research

Resources; Notice of Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as